Fig. 5
TRX1 depletion limits CRPC tumor formation by LNAI and LNCaP SB5 cells. a Tumor endpoint volumes, at 4 weeks post-injection in castrated male Nu/Nu mice, of LNAI cells transduced with either shLuc or shTRX1 (n = 11 per group). Error bars represent ± SD. The p-value was determined via a two-tailed Student’s t-test. b Western blot of total protein lysates (30 µg) from the indicated groups of LNAI tumors was probed with the described antibodies. Both sets of samples were run under identical conditions and developed concurrently in the same cassette. Loading (GAPDH) is shown for separate runs using the same lysates. Note that the TRX1 blots are deliberately overexposed to show the extent of knockdown in the shTRX1 samples. c Quantitation of signal from all the tumors in each group from (b), normalized to GAPDH. Results are derived from two independent blots and error bars are ± SD. The p-values were determined via a two-tailed Student’s t-test. d H&E staining and immunohistochemical staining for Ki67 or AR from a representative tumor per cohort. The size bar, in white, is relevant for each panel and represents a 100 µm scale. e Fold-changes in indicated parameters for LNAI shTRX1 tumors normalized to shLuc tumor values. The p-values were determined via a two-tailed Student’s t-test. f Tumor endpoint volumes, at 7 weeks post-injection in castrated male Nu/Nu mice, of LNCaP SB5 cells transduced with either shLuc or shTRX1 (n = 12 per group). Error bars represent ± SD. The p-value was determined via a Welch’s t-test due to unequal variances
